Faron, etusivu

releases and publications

Faron notice of EGM

Regulatory

Faron Announces Top-Line 12-Month Survival Results

Regulatory

First Patient Dosed in Ph I/II BEXMAB Combo Study

Exercise of options

Regulatory

Presentation of Biomarker Analysis at ASCO

Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies

Regulatory

Ex Vivo Data Presented at EHA2022 Congress

Mol Cancer Ther Publishes Bexmarilimab Research

Grant of options

Insider Transaction Regulatory

Board Changes

Regulatory
PreviousNext
Back to top